Fiche centre
University of Pittsburgh
Pittsburgh — United States
Essais liés19clinical trials
VillePittsburghlocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT05799755
Essais cliniques associés
19| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Nintedanib | Myopathies | Phase 4 | NCT05799755 | MINT — Myositis Interstitial Lung Disease Nintedanib Trial | COMPLETED |
| Vamorolone | Myopathies | Phase 2 | NCT05166109 | A Study to Assess Vamorolone in Becker Muscular Dystrophy (BMD) | COMPLETED |
| Direct cortical stimulation and deep brain stimulation of motor thalamus | Parkinson | Non applicable | NCT07056361 | Stimulating Specific Brain Areas (VOP/VIM) With Electricity to Improve Movement and Muscle Control | RECRUITING |
| 18F-Flortaucipir radiopharmaceutical | Alzheimer | Phase 1 | NCT05361382 | Head-to-Head Harmonization of Tau Tracers in Alzheimer's Disease | ACTIVE_NOT_RECRUITING |
| Ocrelizumab | SEP | Phase 1 | NCT03972306 | A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple Sclerosis | COMPLETED |
| Ocrelizumab | SEP | À vérifier | NCT02807285 | Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis | NO_LONGER_AVAILABLE |
| Intravenously administered pooled human immunoglobulin (IVIG) | Myopathies | Phase 2 | NCT06599697 | The MIGHT Trial - An Exploratory Clinical Trial of IVIG in Anti-HMGCR Immune Mediated Necrotizing Myopathy | RECRUITING |
| Neuraceq | Alzheimer | À vérifier | NCT05617014 | ADNI4 — Alzheimer's Disease Neuroimaging Initiative 4 | ENROLLING_BY_INVITATION |
| Ianalumab | Lupus | Phase 3 | NCT05639114 | Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1) | ACTIVE_NOT_RECRUITING |
| 3T Magnetic Resonance Imaging (MRI) | Épilepsie | À vérifier | NCT05823766 | Transforming Research and Clinical Knowledge in Traumatic Brain Injury Epileptogenesis Project (TRACK-TBI EPI) | ACTIVE_NOT_RECRUITING |
| Positive airway pressure | Alzheimer | Non applicable | NCT05988385 | ESSENTIAL — The Effects of Successful OSA Treatment on Memory and AD Biomarkers in Older Adults Study | RECRUITING |
| HART — Evaluating the Effectiveness of the Health App Recommendation Tool | Alzheimer | Non applicable | NCT07216716 | HART — Evaluating the Effectiveness of the Health App Recommendation Tool | RECRUITING |
| Mycophenolate Mofetil | Myasthénie | À vérifier | NCT03490539 | PROMISE-MG — Disease-Modifying Treatments for Myasthenia Gravis | COMPLETED |
| Sevasemten 10 mg | Myopathies | Phase 2 | NCT05291091 | Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON) | COMPLETED |
| The Evaluation and Follow-up of Individuals With Memory Disorder | Alzheimer | À vérifier | NCT00001480 | The Evaluation and Follow-up of Individuals With Memory Disorder | COMPLETED |
| ADNI-GO — Alzheimer's Disease Neuroimaging Initiative Grand Opportunity | Alzheimer | À vérifier | NCT01078636 | ADNI-GO — Alzheimer's Disease Neuroimaging Initiative Grand Opportunity | COMPLETED |
| Mexiletine | Sclérose latérale amyotrophique | Phase 2 | NCT02781454 | Mexiletine in Sporadic Amyotrophic Lateral Sclerosis | COMPLETED |
| M5049 dose | Myopathies | Phase 2 | NCT05650567 | Study of M5049 in DM and PM Participants (NEPTUNIA) | TERMINATED |
| Ianalumab | Lupus | Phase 3 | NCT06133972 | SIRIUS-SLE LTE — Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension). | RECRUITING |